Treatment and prevention of learning and memory disorders

Patent metadata

Field	Value
Publication number	US-9198970-B2
Application number	US-201414492240-A
Country	US
Kind code	B2
Filing date	Sep 22, 2014
Priority date	Sep 19, 2012
Publication date	Dec 1, 2015
Grant date	Dec 1, 2015

Abstract

The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

First claim

What is claimed is:

1. A method, comprising:
administering, to the skin of a subject, to enhance learning and/or memory in the subject, a composition comprising an emulsion comprising a first phase comprising an effective amount of molecular nitric oxide and a carrier comprising lecithin containing the molecular nitric oxide, and a second phase comprising an emulsifier, wherein the lecithin is present at at least about 0.25% by weight of the composition, and wherein the composition further comprises no more than about 250 ppm of water by weight of the composition.

2. The method of claim 1 , wherein the subject has a learning or memory disorder.

3. The method of claim 2 , wherein the subject has agnosia.

4. The method of claim 2 , wherein the subject has Alzheimer's disease.

5. The method of claim 2 , wherein the subject has amnesia.

6. The method of claim 2 , wherein the subject has traumatic brain injury.

7. The method of claim 2 , wherein the subject has dementia.

8. The method of claim 2 , wherein the subject has Huntington's Disease.

9. The method of claim 2 , wherein the subject has Parkinson's Disease.

10. The method of claim 2 , wherein the subject has Wernicke-Korsakoff's Syndrome.

11. The method of claim 1 , wherein the lecithin comprises phosphatidylcholine.

12. The method of claim 1 , wherein the lecithin comprises polyenylphosphatidylcholine.

13. The method of claim 1 , wherein the composition comprises a liquid crystal structure comprising the lecithin.

14. The method of claim 1 , wherein the composition is stable at room temperature.

15. The method of claim 1 , wherein the lecithin is present at at least about 30% by weight of the composition.

16. The method of claim 1 , wherein the first phase comprises no more than about 100 ppm of water by weight of the composition.

17. The method of claim 1 , wherein the molecular nitric oxide is present within the composition as a gas.

18. The method of claim 1 , wherein the molecular nitric oxide is bound by hydrogen bonds or van der Waals forces to the lecithin.

19. The method of claim 1 , wherein the nitric oxide is present at at least about 0.5% by weight of the composition without nitric oxide.

20. The method of claim 1 , wherein the composition is a gel.

21. The method of claim 1 , wherein the composition is a cream.

22. A method, comprising:
administering, to the skin of a subject, to enhance learning and/or memory in the subject, a composition comprising an emulsion comprising a first phase comprising an effective amount of molecular nitric oxide and a carrier comprising lecithin containing the molecular nitric oxide, and a second phase comprising an emulsifier, wherein the lecithin is present at at least about 0.25% by weight of the composition, and wherein the composition is stable at room temperature.

23. The method of claim 22 , wherein the lecithin comprises phosphatidylcholine.

24. The method of claim 22 , wherein the lecithin comprises polyenylphosphatidylcholine.

25. The method of claim 22 , wherein the lecithin is present at at least about 0.25% by weight of the composition.

26. The method of claim 22 , wherein the lecithin is present at at least about 30% by weight of the composition.

27. The method of claim 22 , wherein the first phase comprises no more than about 250 ppm of water by weight of the composition.

28. The method of claim 22 , wherein the nitric oxide is present at at least about 0.5% by weight of the composition without nitric oxide.

Assignees

• Transdermal Biotechnology Inc

Inventors

• Perricone Nicholas V

Classifications

• A61K9/0004

  Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas · CPC title

• A61K9/1274

  Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases · CPC title

• A61J1/1412

  Containers with closing means, e.g. caps · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/685

  one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin · CPC title